Atul Deodhar

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Désirée van der Heijde, Atul Deodhar, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2017 · 369 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group

Walter P. Maksymowych, R. Lambert, Mikkel Østergaard et al. · Annals of the Rheumatic Diseases · 2019 · 304 citations · Full text

Medicine, Orthopaedic Surgery, Radiology +17

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

Jürgen Braun, Xenofon Baraliakos, Atul Deodhar et al. · Annals of the Rheumatic Diseases · 2016 · 268 citations · Full text

Medicine, Pharmacotherapy, Inflammation +15

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study

Anna Moltó, Adrien Etcheto, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2015 · 264 citations

Medicine, Internal Medicine, Epidemiology +12